Teleflex Showcases Groundbreaking Research in Urology
WAYNE, Pa. — Teleflex Incorporated (NYSE: TFX), a key player in medical technology, is preparing to unveil several pivotal clinical studies at the upcoming American Urological Association Annual Meeting. This year's gathering is set to take place in Las Vegas and promises to highlight significant advancements in the treatment of benign prostatic hyperplasia (BPH) and innovative techniques for rectal spacing during radiation therapy for prostate cancer.
“It is crucial to understand how leading treatments perform, both in clinical studies and real-life applications,” explained Travis Gay, president and general manager of Teleflex Interventional Urology. “At Teleflex, we are dedicated to fostering evidence-based innovation. Our ongoing research and trials support the careful and effective application of the UroLift™ System and Barrigel™ rectal spacer, which help improve patient outcomes and overall quality of life.”
Highlighting Clinical Studies
The American Urological Association Annual Meeting will feature several important presentations that showcase the outcome of various clinical studies that Teleflex has been part of. Here are some highlights:
CLEAR Randomized Controlled Trial
The CLEAR randomized controlled trial has provided compelling insights, suggesting that patients experience higher satisfaction levels after the UroLift™ PUL treatment compared to Rezum WVTT. This study will be presented in a moderated poster session, allowing for engaging discussions among participants.
IMPACT Randomized Controlled Trial
Another significant study is the IMPACT trial, which focuses on patient experiences and the impact of medication on quality of life. This presentation will underline the differences in patient experience before and after transitioning to UroLift™ therapy, further emphasizing the importance of adaptive care strategies in urology.
AQUA Database Insights
Using data from the American Urological Association Quality Registry, researchers will highlight symptom improvements in patients receiving BPH treatment. This analysis aims to bolster clinical practices by providing evidence of early symptom relief following various interventions.
Safety of Hyaluronic Acid Spacers
A dedicated study led by a team in Australia investigated the safety of stabilized hyaluronic acid as a rectal spacer. The findings indicate a low risk of complications, reinforcing the viability of this approach in radiation therapy.
Educational Opportunities at the AUA
In addition to clinical presentations, Teleflex has organized several educational initiatives at the AUA, reflecting its commitment to advancing urological care.
Semi-Live Barrigel Case Review
This session will provide attendees with an in-depth look at the Barrigel™ rectal spacer, offering technical guidance on its use during procedures.
Advanced Practice Provider Breakfast
Aimed at enhancing collaboration in urology practice, this breakfast will engage APPs in discussions on effective patient care, emphasizing their role in surgical therapies.
Prostate Health Symposium
A noteworthy event during the conference is the Prostate Health Symposium. Leading experts will convene to discuss personalized prostate care and best practices for optimizing outcomes with the UroLift™ System and Barrigel™ rectal spacer.
Daily presentations will occur at the Teleflex booth, focusing on various aspects of the UroLift™ System and Barrigel™ rectal spacer. Attendees will gain valuable insights from experienced practitioners in the field.
About Teleflex Incorporated
Teleflex is committed to improving healthcare quality globally. The company specializes in areas like anesthesia, emergency medicine, interventional cardiology, surgical procedures, and urology. With a diverse product portfolio, including trusted brands like Arrow™, Barrigel™, and UroLift™, Teleflex aims to enhance patient outcomes through innovative solutions.
Frequently Asked Questions
What is the UroLift™ System?
The UroLift™ System is a minimally invasive treatment designed to relieve lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH).
How does the Barrigel™ rectal spacer work?
It positions the rectal wall away from the prostate to minimize radiation exposure during treatment for prostate cancer.
Who can benefit from UroLift™ treatment?
The UroLift™ System is suitable for men over 45 years with symptoms of an enlarged prostate.
Are there any side effects of UroLift™ treatment?
Common side effects include temporary symptoms such as hematuria, pain, and urgency, generally resolving soon after treatment.
Where can I get more information about Teleflex products?
More detailed information can be found on the official Teleflex website.
